Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

摘要: B-lymphocytes are dependent on B-cell receptor (BCR) signaling for the constant maintenance of their physiological function, and in many malignancies this pathway is prone to aberrant activation. This understanding has led an ever-increasing interest networks activated following ligation BCR both normal malignant cells, been critical establishing array small molecule inhibitors targeting BCR-induced signaling. By dissecting how different signal through BCR, researchers contributing design more customized therapeutics which have greater efficacy lower toxicity than previous therapies. allows clinicians access approaches best treat patients whose as a driver pathogenesis.